Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides

Neurobiology of Aging

Volumn 33, Issue 11, 2012, Pages 2704-2714

  Houacine, Jemila ^a   Bolmont, Tristan ^a   Aeschbach, Lorène ^a   Oulad Abdelghani, Mustapha ^b   Fraering, Patrick C ^a  

^a EPFL   (Switzerland)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; EPITOPE; GAMMA SECRETASE; MONOCLONAL ANTIBODY; NOTCH1 RECEPTOR;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BRAIN CORTEX; CARBOXY TERMINAL SEQUENCE; CELL FATE; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED BALB C;

EID: 84858967405     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.12.033     Document Type: Article

References (45)

1. Aguzzi A., Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64:783-790.
2. Alarcon-Segovia D., Ruiz-Argüelles A., Llorente L. Broken dogma: penetration of autoantibodies into living cells. Immunol. Today 1996, 17:163-164.
3. Arbel-Ornath M., Becker M., Rabinovich-Toidman P., Gartner M., Solomon B. Immunomodulation of AbetaPP processing alleviates amyloid-beta-related pathology in Alzheimer's disease transgenic mice. J. Alzheimers Dis 2011, 22:469-482.
4. Beel A.J., Mobley C.K., Kim H.J., Tian F., Hadziselimovic A., Jap B., Prestegard J.H., Sanders C.R. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?. Biochemistry 2008, 47:9428-9446.
5. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol 2010, 224:472-485.
6. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Review Neurosci 2008, 31:175-193.
7. Cacquevel M., Aeschbach L., Osenkowski P., Li D., Ye W., Wolfe M.S., Li H., Selkoe D.J., Fraering P.C. Rapid purification of active gamma-secretase, an intramembrane protease implicated in Alzheimer's disease. J. Neurochem 2008, 104:210-220.
8. Chang Y., Tesco G., Jeong W.J., Lindsley L., Eckman E.A., Eckman C.B., Tanzi R.E., Guénette S.Y. Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1. J. Biol. Chem 2003, 278:51100-51107.
9. de StGroth S.F., Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J. Immunol. Methods 1980, 35:1-21.
10. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398:518-522.
11. Lilly Halts Development of Semagacestat for Alzheimer's disease Based on Preliminary Results of Phase III Clinical Trials 2010, Eli Lilly and Co, Eli Lilly and Co, press release.
12. Fraering P.C. Structural and Functional Determinants of gamma-Secretase, an Intramembrane Protease Implicated in Alzheimer's Disease. Curr. Genomics 2007, 8:531-549.
13. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest 2005, 115:1121-1129.
14. Griffin W.S. Excess betaCTF, not Abeta: the culprit in Alzheimer-related endocytic dysfunction. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1263-1264.
15. Haass C., Capell A., Citron M., Teplow D.B., Selkoe D.J. The vacuolar H(+)-ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type beta-amyloid precursor protein. J. Biol. Chem 1995, 270:6186-6192.
16. Haass C., Selkoe D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993, 75:1039-1042.
17. Hadland B.K., Manley N.R., Su D., Longmore G.D., Moore C.L., Wolfe M.S., Schroeter E.H., Kopan R. Gamma-secretase inhibitors repress thymocyte development. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7487-7491.
18. He G., Luo W., Li P., Remmers C., Netzer W.J., Hendrick J., Bettayeb K., Flajolet M., Gorelick F., Wennogle L.P., Greengard P. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010, 467:95-98.
19. Jameson B.A., Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput. Appl. Biosci 1988, 4:181-186.
20. Khalifa N.B., Van Hees J., Tasiaux B., Huysseune S., Smith S.O., Constantinescu S.N., Octave J.N., Kienlen-Campard P. What is the role of amyloid precursor protein dimerization?. Cell. Adhes. Migration 2010, 4:268-272.
21. King G.D., Scott Turner R. Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?. Exp. Neurol 2004, 185:208-219.
22. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
23. Kukar T.L., Ladd T.B., Bann M.A., Fraering P.C., Narlawar R., Maharvi G.M., Healy B., Chapman R., Welzel A.T., Price R.W., Moore B., Rangachari V., Cusack B., Eriksen J., Jansen-West K., Verbeeck C., Yager D., Eckman C., Ye W., Sagi S., Cottrell B.A., Torpey J., Rosenberry T.L., Fauq A., Wolfe M.S., Schmidt B., Walsh D.M., Koo E.H., Golde T.E. Substrate-targeting gamma-secretase modulators. Nature 2008, 453:925-929.
24. Langui D., Girardot N., El Hachimi K.H., Allinquant B., Blanchard V., Pradier L., Duyckaerts C. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am. J. Pathol 2004, 165:1465-1477.
25. Lazarov V.K., Fraering P.C., Ye W., Wolfe M.S., Selkoe D.J., Li H. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6889-6894.
26. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat. Rev 2010, 6:108-119.
27. Liao Y.F., Wang B.J., Cheng H.T., Kuo L.H., Wolfe M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem 2004, 279:49523-49532.
28. Lobo E.D., Hansen R.J., Balthasar J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci 2004, 93:2645-2668.
29. Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010, 9:702-716.
30. Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., Games D., Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
31. Miyashita N., Straub J.E., Thirumalai D. Structures of beta-amyloid peptide 1-40, 1-42, and 1-55-the 672-726 fragment of APP-in a membrane environment with implications for interactions with gamma-secretase. J. Am. Chem. Soc 2009, 131:17843-17852.
32. Osenkowski P., Li H., Ye W., Li D., Aeschbach L., Fraering P.C., Wolfe M.S., Selkoe D.J., Li H. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. J. Mol. Biol 2009, 385:642-652.
33. Paganetti P., Calanca V., Galli C., Stefani M., Molinari M. Beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J. Cell Biol 2005, 168:863-868.
34. Perriard J., Jaunin F., Favre B., Büdinger L., Hertl M., Saurat J.H., Borradori L. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J. Invest. Dermatol 1999, 112:141-147.
35. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jäggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Hölscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006, 7:940-946.
36. Rajendran L., Honsho M., Zahn T.R., Keller P., Geiger K.D., Verkade P., Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11172-11177.
37. Russo C., Callegaro L., Lanza E., Ferrone S. Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J. Immunol. Methods 1983, 65:269-271.
38. Sannerud R., Annaert W. Trafficking, a key player in regulated intramembrane proteolysis. Semin. Cell Dev. Biol 2009, 20:183-190.
39. Scheuermann S., Hambsch B., Hesse L., Stumm J., Schmidt C., Beher D., Bayer T.A., Beyreuther K., Multhaup G. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J. Biol. Chem 2001, 276:33923-33929.
40. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev 2001, 81:741-766.
41. Siemers E.R., Quinn J.F., Kaye J., Farlow M.R., Porsteinsson A., Tariot P., Zoulnouni P., Galvin J.E., Holtzman D.M., Knopman D.S., Satterwhite J., Gonzales C., Dean R.A., May P.C. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006, 66:602-604.
42. Tampellini D., Magrané J., Takahashi R.H., Li F., Lin M.T., Almeida C.G., Gouras G.K. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J. Biol. Chem 2007, 282:18895-18906.
43. Vitelli R., Santillo M., Lattero D., Chiariello M., Bifulco M., Bruni C.B., Bucci C. Role of the small GTPase Rab7 in the late endocytic pathway. J. Biol. Chem 1997, 272:4391-4397.
44. Wang A., Das P., Switzer R.C., Golde T.E., Jankowsky J.L. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci 2011, 31:4124-4136.
45. Wong G.T., Manfra D., Poulet F.M., Zhang Q., Josien H., Bara T., Engstrom L., Pinzon-Ortiz M., Fine J.S., Lee H.J., Zhang L., Higgins G.A., Parker E.M. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem 2004, 279:12876-12882.